Products

1985668-78-7, i.e., 5-Pyrimidineacetamide, 2-butyl-1-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1,6-dihydro-N,N,4-trimethyl-6-oxo-, is an organic compound related to non-marsartan (Fimasartan), Fimarsartan is an angiotensin II receptor antagonist (ARB) used to treat hypertension. 

2-(2-butyl-4-hydroxy-6-methylpyrimidin-5-yl)-N,N-dimethylacetamide (BMP) is an organic synthetic compound. 

503155-67-7, the non-marsartan intermediate DCMP, is an important organic compound, mainly used as a synthetic intermediate of non-marsartan (Fimasartan). Fimarsartan is an angiotensin II receptor antagonist (ARB) used to treat hypertension. 

Dotinurad (CAS number: 1285572-51-1), also known as doltenorel, is a novel urate-stimulating acid excretion drug jointly developed by Fuji Yakuhin and Eisai. The drug is mainly used for the treatment of hyperuricemia and gout, and its mechanism of action is to reduce the reabsorption of uric acid by selectively inhibiting urate transporter 1 (URAT1), thereby increasing uric acid excretion and reducing uric acid levels in the blood. Doltenolabil was approved for marketing in Japan on January 23, 2020, and received NDA acceptance at the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China on January 22, 2024.